TP53 and head and neck squamous cell carcinoma: PHLDA3 also shows promise as a biomarker for HNSCC, with elevated expression correlating with better prognosis in patients with wild-type p53, while lower expression in p53-mutated SCCs is linked to poorer outcomes [11].